PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Itraconazole

Drugs in development · updated 30 October 2026

Itraconazole: clinical trials and development status

Other names and codes: Tolsura, Onmel, Sporanox

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Itraconazole is in 55 active clinical trials (recruiting or ongoing, phases I–III) for 43 diseases. The most advanced phase is III.

55Active trials
IIIMost advanced phase
43Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Itraconazole and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 43 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Allergic bronchopulmonary aspergillosisIII1NCT06174922
AspergillosisIII1NCT07825259
BronchiectasisIII1NCT06160713
Non-small-cell lung carcinomaI–II5NCT05914116
Breast neoplasmI–II3NCT05579366
Endometrial neoplasmI–II3NCT05579366
Esophageal squamous cell carcinomaII3NCT05563766
Ovarian neoplasmI–II3NCT05579366
Triple-negative breast neoplasmI–II3NCT05579366
Uterine cervix neoplasmI–II3NCT05914116
Acute myeloid leukemiaII2NCT07069933
Barrett's esophagusII2NCT06732388
Biliary tract neoplasmI–II2NCT05150691
Esophagus adenocarcinomaII2NCT05563766
Fallopian tube neoplasmI–II2NCT05579366
Head and neck squamous cell carcinomaI–II2NCT05914116
Hepatocellular carcinomaI–II2NCT05914116
Lung small cell carcinomaI–II2NCT05914116
MelanomaI–II2NCT05914116
MetastasisI–II2NCT05150691
Stomach neoplasmI–II2NCT07070232
Acute biphenotypic leukaemiaI–II1NCT04067336
Bile duct neoplasmI–II1NCT05150691
CarcinomaI–II1NCT05150691
CholangiocarcinomaI–II1NCT05150691
Gastrointestinal neoplasmI–II1NCT05150691
Hematologic neoplasmI–II1NCT04067336
LeukemiaI–II1NCT04067336
Liver neoplasmI–II1NCT05150691
MesotheliomaI–II1NCT05579366

Everything on Itraconazole

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch